Immuron (IMRN) Non-Current Assets (2016 - 2025)
Immuron (IMRN) posted quarterly Non-Current Assets of $1146.2 for Q3 2025, down 86.08% year-over-year from $8236.3 in Q3 2024, and down 98.44% quarter-over-quarter from $73403.9 in Q2 2025.
Immuron (IMRN) Non-Current Assets (2016 - 2025) Analysis & Trends
Immuron's Non-Current Assets history runs 10 years deep, the most recent figure standing at $1146.2 for Q3 2025.
- In Q3 2025, Non-Current Assets fell 86.08% year-over-year to $1146.2; the TTM figure through Sep 2025 stood at $353791.9 (down 77.78% YoY), while the FY2025 annual figure was $1146.2, down 86.08% from the prior year.
- Non-Current Assets for Q3 2025 stood at $1146.2, down from $73403.9 in the prior quarter.
- The five-year high for Non-Current Assets was $1.0 million in Q3 2023, with the low at -$18.7 million in Q4 2021.
- The 5-year median for Non-Current Assets is $172204.7 (2024), against an average of -$1.9 million.
- The sharpest annual moves came in 2021 and 2024: Non-Current Assets plunged 105077.14% in 2021, then surged 4347.25% in 2024.
- Immuron's Non-Current Assets stood at -$18.7 million in 2021, then jumped by 104.17% to $777698.3 in 2022, then plunged by 99.22% to $6093.8 in 2023, then surged by 4347.25% to $271005.5 in 2024, then plunged by 99.58% to $1146.2 in 2025.
- Business Quant data shows IMRN's Non-Current Assets at $1146.2 in Q3 2025, $73403.9 in Q2 2025, and $271005.5 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Immuron | 6.81 Mn | 6.78 Mn | - | -99,780.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 1,146.16 |
| Jun 30, 2025 | 73,403.89 |
| Dec 31, 2024 | 271,005.50 |
| Sep 9, 2024 | 8,236.32 |
| Jun 30, 2024 | 542,793.65 |
| Dec 31, 2023 | 6,093.77 |
| Sep 28, 2023 | 1.03 Mn |
| Aug 30, 2023 | -204,093.37 |
| Jun 30, 2023 | -13.42 Mn |
| Dec 31, 2022 | 777,698.31 |
| Aug 31, 2022 | 823,152.59 |
| Jun 30, 2022 | 847,826.76 |
| Dec 31, 2021 | -18.67 Mn |
| Jun 30, 2021 | 1.00 Mn |
| Dec 31, 2020 | 17,780.76 |
| Sep 1, 2020 | -4.41 Mn |
| Jun 30, 2020 | 1.18 Mn |
| Dec 31, 2019 | 17,931.22 |
| Jun 30, 2019 | 1.32 Mn |
| Dec 31, 2018 | 646,638.00 |